Whole exome sequencing refers to the process of determining the sequence of protein-coding regions of all genes in the human genome. It is widely used by researchers and clinicians for identifying potential disease-causing variants. Whole exome sequencing offers significant advantages over traditional gene panels and single-gene testing methods as it allows for the simultaneous analysis of all protein-coding genes that are known to be associated with various genetic disorders. Over the past decade, the cost of whole exome sequencing has declined dramatically making it a viable alternative for testing hundreds of genes simultaneously.
The global whole exome sequencing market is estimated to be valued at USD 1.80 Bn in 2024 and is expected to reach USD 4.72 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 14.8% from 2024 to 2031.
Key Takeaways
Key players operating in the Whole Exome Sequencing are Illumina Inc, Thermo Fisher Scientific Inc, F. Hoffmann-La Roche AG, Agilent Technologies, Eurofins Scientific, GENEWIZ, Macrogen Inc.
Rising incidence of chronic diseases coupled with increasing emphasis on early disease diagnosis is a major factor driving the demand for whole exome sequencing procedures. According to various studies, around 80-90% of the genetic contribution to human phenotypic variability is thought to be associated with changes in the exome.
The expanding applications of Whole Exome Sequencing Market Growth sequencing beyond rare genetic disorders into fields like oncology, cardiology and preimplantation genetic testing is expected to accelerate the market growth. Key players are actively exploring opportunities in emerging economies in Asia Pacific and Latin America through partnerships and collaborations.
Explore More Related Article On – Whole Exome Sequencing Market
Get More Insights on- Whole Exome Sequencing Market
